A forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals Ltd has received PAS approval from the US Food & Drug Administration for its sANDA Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global musculoskeletal disorders drugs market as it emerges from the COVID-19 shut down.
The global musculoskeletal disorders drugs market is expected to grow from $81.08 billion in 2020 to $85.6 billion in 2021 at a compound annual growth rate (CAGR) of 5.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $100.76 billion in 2025 at a CAGR of 4%.